Instem plc Director/PDMR Shareholding (1276D)

TIDMINS

RNS Number : 1276D

Instem plc

29 January 2018

Instem plc

("Instem" or the "Company")

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, was notified on 25 January 2018, that the DG 2008 Discretionary Settlement (of which David Gare (the Company chairman) and his wife are the trustees) transferred 70,000 ordinary shares of 10p each in the Company ("Ordinary Shares") to David's son Adrian Gare and a further 70,000 to his daughter, Deborah Walker, for nil consideration. Following the transaction, the DG 2008 Discretionary Settlement now has a total interest in 1,258,427 Ordinary Shares, representing 7.92% of the Company's issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1     Details of the person discharging 
        managerial responsibilities / person 
        closely associated 
----  ---------------------------------------------------------------- 
 a)    Name                       David Gare and his wife 
                                   (via the DG 2008 Discretionary 
                                   Settlement) 
----  -------------------------  ------------------------------------- 
 2     Reason for the notification 
----  ---------------------------------------------------------------- 
 a)    Position/status            Chairman of the Company 
----  -------------------------  ------------------------------------- 
 b)    Initial notification       Initial 
        /Amendment 
----  -------------------------  ------------------------------------- 
 3     Details of the issuer, emission allowance 
        market participant, auction platform, 
        auctioneer or auction monitor 
----  ---------------------------------------------------------------- 
 a)    Name                       Instem plc 
----  -------------------------  ------------------------------------- 
 b)    LEI                        213800PILYUFNNROQX68 
----  -------------------------  ------------------------------------- 
 4     Details of the transaction(s): section 
        to be repeated for (i) each type of 
        instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place 
        where transactions have been conducted 
----  ---------------------------------------------------------------- 
 a)    Description                Ordinary shares of 10p 
        of the financial           each 
        instrument, 
        type of instrument 
---- 
 
       Identification             GB00B3TQCK30 
        code 
 
 b)    Nature of                  Transfer of ordinary shares 
        the transaction 
----  -------------------------  ------------------------------------- 
 c)    Price(s) and 
        volume(s) 
----                              ---------------  ----------------- 
                                   Price(s)         Volume(s) 
----                              ---------------  ----------------- 
                                   0p               140,000 
                                  ---------------  ----------------- 
 
 d)    Aggregated 
        information 
---- 
 
  - Aggregated               N/A 
   volume 
 
  - Price 
 
 e)    Date of the                25 January 2018 
        transaction 
----  -------------------------  ------------------------------------- 
 f)    Place of the               London Stock Exchange 
        transaction                (XLON) 
----  -------------------------  ------------------------------------- 
 

For further information, please contact:

 
 Instem plc                 [phone] 
 Phil Reason, CEO 
 Nigel Goldsmith, CFO 
 
 
   N+1 Singer (Nominated 
   Adviser & Broker)          [phone] 
 Richard Lindley 
  James White 
 
 
   Walbrook Financial PR      [phone] 
 Paul Cornelius             [e-mail] 
 Helen Cresswell 
  Sam Allen 
 
 

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

Instem solutions are in use by customers worldwide and enable our clients to bring life enhancing products to market faster.

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.

To learn more about Instem solutions and its mission, please visit instem.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHBCGDBXUDBGII

(END) Dow Jones Newswires

January 29, 2018 02:00 ET (07:00 GMT)